ChromaDex Corporation

Equities

CDXC

US1710774076

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
3.48 USD -5.18% Intraday chart for ChromaDex Corporation +8.75% +143.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating MT
Transcript : ChromaDex Corporation, Q4 2023 Earnings Call, Mar 06, 2024
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, vs. Street Est of $20.7M MT
ChromaDex Corporation Provides Earnings Guidance for 2024 CI
ChromaDex Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ChromaDex Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ChromaDex Corporation, Chromadex, Inc. and ChromaDex Analytics, Inc Enter into an Amendment to the Business Financing Agreement Dated November 1, 2019 Among the Borrowers and Western Alliance Bank CI
Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+ CI
ChromaDex Says High-Dose Niagen Safe for Parkinson's Disease Patients in Phase 1 Study MT
Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD) CI
ChromaDex Reports Positive Data From Phase 2 Study Using Niagen MT
Chromadex Corp. Shares Results from Phase II Clinical Study CI
Transcript : ChromaDex Corporation, Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (CDXC) CHROMADEX CORPORATION Posts Q3 Revenue $19.5M, vs. Street Est of $20.4M MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023 CI
ChromaDex Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ChromaDex Launches New Food Supplement MT
ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside) CI
ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ?Healthy Aging? Line CI
Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside CI
ChromaDex Corporation(NasdaqCM:CDXC) dropped from S&P Global BMI Index CI
Transcript : ChromaDex Corporation, Q2 2023 Earnings Call, Aug 09, 2023
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q2 Revenue $20.3M, vs. Street Est of $19.5M MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023 CI
ChromaDex Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart ChromaDex Corporation
More charts
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.48 USD
Average target price
5.73 USD
Spread / Average Target
+64.66%
Consensus
  1. Stock
  2. Equities
  3. Stock ChromaDex Corporation - Nasdaq
  4. News ChromaDex Corporation
  5. HC Wainwright Adjusts Price Target on ChromaDex to $7 From $8, Reiterates Buy Rating